Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MarketBeat

Palantir’s $100M Nuclear OS Pact Boosts Bullish Case

Palantir lands a $100M deal to modernize nuclear power with AI, boosting its long-term prospects despite recent stock volatility

Why McCormick Stock Could Soar After Durables Data Surprise

Why McCormick Stock Could Soar After Durables Data Surprise

McCormick stock jumps on better-than-expected Durable Goods orders for the United States, setting the stage for a continuation rally ahead.

RTX Corporation Stock: $93B Defense Backlog Fuels Growth

RTX Corporation Stock: $93B Defense Backlog Fuels Growth

With a massive defense backlog and surging commercial aftermarket, RTX offers investors a compelling blend of security and powerful growth potential.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analysts Are All In on This Tech Stock—Why You Should Be, Too

Silicon Motion's unique combination of sound management, strong fundamentals, crucial and niche tech, and analyst enthusiasm point to continued success.

3 Safe Buy-and-Hold Dividend Stocks With Strong Balance Sheets

These 3 dividend stocks offer strong balance sheets, low debt, and reliable payouts, making them solid long-term picks for income investors

Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy

A rotation into value stocks might be imminent in the market today, and investors should be positioned before it happens to them by surprise.

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

inkl

Read news from The Economist, FT, and more,
with one subscription

Buybacks Galore: Repurchases From the Oval Office to Olive Garden

Buybacks Galore: Repurchases From the Oval Office to Olive Garden

After securing funding for a Bitcoin treasure chest, Trump's social media stock is among three big names that are gearing up for significant buyback spending.

Lululemon Slips as Rivals Rally: 3 Stocks to Watch

Lululemon Slips as Rivals Rally: 3 Stocks to Watch

Lululemon's Q2 report highlighted the challenges of dealing with tariffs. But not all apparel stocks are struggling; here are three beating estimates in 2025.

The Top Insider Sells From Q2: Buy, Sell, or Hold?

The Top Insider Sells From Q2: Buy, Sell, or Hold?

Insiders are selling stocks like Meta Platforms, Carvana, and Magnite in 2025, but investors should think twice. Trends suggest new highs could be reached.

Why BigBear.ai Could Rally 100% and Catch Palantir Soon

Why BigBear.ai Could Rally 100% and Catch Palantir Soon

Bigbear.ai keeps making new breakthroughs in its way to higher prices, a story that investors need to keep track of for their portfolio upside.

5 High-Yielding ETFs to Buy and Hold Forever

5 High-Yielding ETFs to Buy and Hold Forever

Dividend ETFs remain a reliable long-term strategy, offering steady income, compounding growth, and low-cost exposure to blue-chip companies.

Alphabet’s Waymo and Services Beginning to Feel the Pressure?

Alphabet’s Waymo and Services Beginning to Feel the Pressure?

Waymo remains a significant long-term opportunity for Alphabet, but profitability, competition, and regulatory challenges persist.

S&P 500 All-Time Highs: 5 Catalysts Driving It Higher

S&P 500 All-Time Highs: 5 Catalysts Driving It Higher

The S&P 500 is expected to continue rising in 2025, as leading stocks are at or on the cusp of new highs, driven by bullish fundamentals and catalysts.

Get all your
news in one place.

100’s of premium titles.
One news app.

3 Dividend Kings Trading at Rare Discounts to Buy This Summer

Here are 3 Dividend Kings (HRL, GPC, PG) currently trading near long-term lows, offering attractive yields and growth potential, to buy this summer.

3 Summer Short-Squeeze Candidates With Catalysts for Covering

Short squeeze candidates SoundHound AI, Etsy, and Brinker International are fundamentally sound businesses with analysts' support.

3 Must-Watch Stocks Poised to Benefit from GENIUS Act Stablecoins

The GENIUS Act outlines a regulatory framework for stablecoins, digital tokens designed to maintain a $1 value. What stocks stand to benefit most from the bill?

Durable Goods Orders Jump 16.5%—Top 3 Stocks to Own Now

Durable goods orders surged in June. Here are three stocks that could gain from a stronger economic outlook in the second half

Get all your
news in one place.

100’s of premium titles.
One news app.

Top 5 Stocks for July: Momentum-Driven Picks to Watch Now

July is expected to be a hot month, but not hotter than the markets for these stocks, which are rising due to factors such as results, guidance, and analysts.

AutoNation: Growth Engines Make It an Undervalued Stock

AutoNation’s value lies in its high-margin service and finance divisions, a fundamental strength that suggests its current stock price is undervalued.

Snowflake Hits 52-Week High—Options Traders Bet on Further Rally

A new wave of call option traders have found a reason to place a big bet that Snowflake stock may be pushing for higher prices in the near future.

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making?

Apple has been a dud in 2025. But, the firms dominance in the device market gives it time to catch up and cash in on a world of AI opportunity long-term.

Value Alert: 3 High-Yield Stocks Trading at 52-Week Lows

Stocks trading near their 52-week lows offer opportunity and higher yields but come with risk. The question is if these three stocks are a buy, sell, or hold?

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

People

125,296 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

284,393 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play